Abdulkareem Sultan Al Olama – CEO, Al Jalila Foundation, UAE
Dr Abdulkareem Sultan Al Olama, CEO of the Al Jalila Foundation, discusses the Foundation’s goal to position the UAE at the forefront of medical education and research, the importance of…
Al Jalila Foundation, a global philanthropic organisation dedicated to transforming lives through medical research, education and treatment was founded by His Highness Sheikh Mohammed Bin Rashid Al Maktoum, Vice-President and Prime Minister of the United Arab Emirates (UAE) and Ruler of Dubai in April 2013, to position Dubai and the UAE at the forefront of medical innovation.
Al Jalila Foundation promotes medical education and research by investing in the UAE’s medical treatment capabilities; it provides scholarships to nurture a home-grown generation of medical professionals and supports ground-breaking research that addresses health challenges prevalent in the region. Al Jalila Foundation Research Centre, located in Dubai Healthcare City, is a beacon for regionally-relevant medical innovation produced by home-grown biomedical researchers. The UAE’s first independent multi-disciplinary medical research centre focuses on five of the most pressing regional health challenges: cancer, cardiovascular diseases, diabetes, obesity and mental health. Benefitting from the Foundation’s global outreach, Al Jalila Foundation Research Centre brings together international best practice and regional expertise in a cultivating environment with state-of-the-art facilities.
Contact
Al Jalila Foundation, First Floor, Building 12, Dubai Healthcare City
P.O. Box 300100, Dubai, United Arab Emirates
Tel: +971 4 383 8000
Dr Abdulkareem Sultan Al Olama, CEO of the Al Jalila Foundation, discusses the Foundation’s goal to position the UAE at the forefront of medical education and research, the importance of…
As Abu Dhabi translates strategy into execution, the focus turns from platform design to operational delivery. Albarah Elkhani, COO of Integrated Health Solutions at M42, details how large-scale genomics, clinical…
Healthcare systems across the world continue to struggle with fragmentation, rising costs and reactive models of care that intervene too late. Dimitris Moulavasilis, Group CEO of M42, outlines how an…
For decades, the Middle East has faced a disproportionately high burden of rare genetic disorders, fuelled both by deep-rooted cultural practices and an overreliance on Western genomic data. Fast forward…
In less than a decade, the Abu Dhabi Stem Cells Center has emerged as a central pillar in the UAE’s ambition to build a fully integrated ecosystem for advanced therapies.…
Global advances in rare blood disorders increasingly hinge on where evidence is generated, how patients are followed, and whether innovation reaches beyond a limited few. Khaled Musallam describes how clinical…
CTI EMEA Managing Director Alaa Assem is a physician, ophthalmologist and MBA holder with over 30 years of experience in pharma and clinical research organisations. Since joining CTI, he has…
Rare diseases remain among the most complex and least visible challenges facing healthcare systems, particularly in regions where genetic factors amplify the burden. In this conversation, Ahmed Salem, Head of…
As healthcare systems across the GCC accelerate their focus on innovation, access, and advanced therapies, Novartis is positioning the region at the centre of its long-term strategy. Mohamed Ezz Eldin…
Biogen’s transformation into a rare disease-focused organisation is reshaping how innovation reaches patients in the GCC. Diederik Kok, the company’s GCC Head reflects on how global strategy translates into regional…
Hussein Abhari, Head of the MENA region, QIAGEN, has led the company’s regional presence since 2017, spanning products for molecular research and clinical testing. His priorities focus on strengthening long-term…
Dr Rania Alshami reflects on two decades in the Middle East and North Africa clinical research ecosystem, charting the region’s regulatory maturation, rare disease opportunities, and growing role in early-phase…
Adeeb Al Attar leads Genpharm at a point where rare and advanced therapies in the Middle East face a more exacting test. Scale and ambition are no longer enough. What…
See our Cookie Privacy Policy Here
